Effect of Opioid Use on Immune Activation and HIV Persistence on ART.

Abstract

While there is an emerging consensus that engagement of the Mu opioid receptor by opioids may modulate various stages the HIV life cycle (e.g.: increasing cell susceptibility to infection, promoting viral transcription, and depressing immune responses to virally-infected cells), the overall effect on latency and viral reservoirs remains unclear. Importantly, the hypothesis that the increase in immune activation observed in chronic opioid users by direct or indirect mechanisms (i.e., microbial translocation) would lead to a larger HIV reservoir after ART-suppression has not been supported to date. The potential for a subsequent decrease in reservoirs after ART-suppression has been postulated and is supported by early reports of opioid users having lower latent HIV burden. Here, we review experimental data supporting the link between opioid use and HIV modulation, as well as the scientific premise for expecting differential changes in immune activation and HIV reservoir between different medications for opioid use disorder. A better understanding of potential changes in HIV reservoirs relative to the engagement of the Mu opioid receptor and ART-mediated immune reconstitution will help guide future cure-directed studies in persons living with HIV and opioid use disorder. Graphical Abstract Review. HIV replication, immune activation and dysbiosis: opioids may affect immune reconstitution outcomes despite viral suppression.

• Authors: Livio Azzoni, David Metzger, Luis J Montaner
• Journal: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology (J Neuroimmune Pharmacol) Vol. 15 Issue 4 Pg. 643-657 (12 2020) ISSN: 1557-1904 [Electronic] United States
• PMID: 32974750 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Analgesics, Opioid
• Anti-Retroviral Agents

Topics

• Analgesics, Opioid (adverse effects)
• Animals
• Anti-Retroviral Agents (pharmacology, therapeutic use)
• Dysbiosis (epidemiology, immunology)
• HIV Infections (drug therapy, epidemiology, immunology)
• HIV-1 (drug effects, immunology)
• Humans
• Immunity, Innate (drug effects, immunology)
• Opioid-Related Disorders (epidemiology, immunology)